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Pannexin1 (Panx1) channels release cytosolic ATP in response to signaling pathways. Panx1
is highly expressed in the central nervous system. We used four antibodies with different
Panx1 anti-peptide epitopes to analyze four regions of rat brain. These antibodies labeled
the same bands in Western blots and had highly similar patterns of immunofluorescence
in tissue culture cells expressing Panx1, but Western blots of brain lysates from Panx1
knockout and control mice showed different banding patterns. Localizations of Panx1 in
brain slices were generated using automated wide field mosaic confocal microscopy for
imaging large regions of interest while retaining maximum resolution for examining cell
populations and compartments. We compared Panx1 expression over the cerebellum, hip-
pocampus with adjacent cortex, thalamus, and olfactory bulb. While Panx1 localizes to
the same neuronal cell types, subcellular localizations differ. Two antibodies with epitopes
against the intracellular loop and one against the carboxy terminus preferentially labeled
cell bodies, while an antibody raised against an N-terminal peptide highlighted neuronal
processes more than cell bodies. These labeling patterns may be a reflection of different
cellular and subcellular localizations of full-length and/or modified Panx1 channels where
each antibody is highlighting unique or differentially accessible Panx1 populations. How-
ever, we cannot rule out that one or more of these antibodies have specificity issues. All
data associated with experiments from these four antibodies are presented in a manner
that allows them to be compared and our claims thoroughly evaluated, rather than elimi-
nating results that were questionable. Each antibody is given a unique identifier through
the NIF Antibody Registry that can be used to track usage of individual antibodies across
papers and all image and metadata are made available in the public repository, the Cell
Centered Database, for on-line viewing, and download.
Keywords: purinergic receptors, pannexin channels,ATP signaling, large field mosaic fluorescent imaging, paracrine
signaling, connexin, knockout mouse
INTRODUCTION
One mechanism of paracrine cell–cell communication occurs by
ATP release and signal transduction through purinergic receptors
(Burnstock, 2011). In the nervous system, ATP signaling stimu-
lates neurotransmission, neuromodulation, and secretion as well
as playing a role in cell proliferation, differentiation, and inflam-
mation (Fields and Stevens, 2000). Membrane bound purinergic
receptors are found on the plasma membrane of neurons and
non-neuronal cells such as astrocytes and microglia (Fields and
Stevens, 2000). Several studies have shown an association of the
purinergic receptors with pannexin1 (Panx1), a connexin-like
protein, which when stimulated acts as an ATP release channel
(Locovei et al., 2006b; Nishida et al., 2008; Silverman et al., 2009;
Kim and Kang, 2011; Poornima et al., 2011; Vessey et al., 2011).
Abbreviations: CNS, central nervous system; Panx1, pannexin1.
In situ hybridization imaging demonstrated high expression levels
of Panx1 mRNA in the central nervous system (Ray et al., 2005;
Vogt et al., 2005).
Panx1 has been proposed to fulfill a function in adap-
tive/inflammation responses following specific stimuli (Sosinsky
et al., 2011). Panx1 channels have been shown to release ATP dur-
ing gustatory channel response in taste bud cells (Romanov et al.,
2007), the activation of the immune response in macrophages
(Pelegrin and Surprenant, 2006), T lymphocytes (Schenk et al.,
2008), and neurons (Silverman et al., 2009), pressure overload-
induced fibrosis in the heart (Nishida et al., 2008) and NMDA
receptor epileptiform electrical activity in the hippocampus
(Thompson et al., 2008). This signaling pathway involves an “ATP-
induced ATP release” mechanism whereby ATP stimulation of
ionotropic P2X or metabotropic P2Y receptors signals intracel-
lular components that favor opening of Panx1 channels (pan-
nexons). ATP is then released from cells. Higher concentration
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of extracellular ATP released from the cell then acts to close the
open pannexon in a negative feed-back loop (Qiu and Dahl, 2009).
Linked to paracrine (calcium) wave signaling, this “ATP-induced
ATP release” allows for a small, localized number of cells to be
stimulated and respond to stresses such as metabolic inhibition,
mechanical stress and invading pathogens (Dubyak, 2009). Panx1
is part of the cryopyrin and neuronal inflammasome (Kanneganti
et al., 2007; Silverman et al., 2009). The inflammasome is responsi-
ble for activation of inflammatory processes and induces pyropto-
sis, a process of programmed cell death distinct from apoptosis. In
particular, Panx1 has been found to co-immunoprecipitate with
components of the neuronal inflammasome suggesting that the
central nervous system (CNS) inflammasome is pre-formed (Sil-
verman et al., 2009). A recent study showed that Panx1 channels in
the hippocampus contributed to seizures by releasing ATP when
induced by kainic acid and that deletion of Panx1 or the Panx1
channel blocker reduced the amount of ATP that is released and
improves the behavioral manifestation of seizures (Santiago et al.,
2011).
Immunolabeling studies have shown that Panx1 is widely
expressed in cells throughout the body such as CNS neurons, lens
epithelial cells, retinal sensory cells, astrocytes, erythrocytes, car-
diac myocytes, and macrophages (Dvoriantchikova et al., 2006a;
Dvoriantchikova et al., 2006b; Locovei et al., 2006a; Zappala
et al., 2006; Zoidl et al., 2007; Karpuk et al., 2011; Kienitz et al.,
2011). However, its cellular and subcellular protein distributions
in brain regions have not been thoroughly characterized across
wide expanses of this complex organ and there have been some
conflicting results among different antibodies (Ray et al., 2006;
Zappala et al., 2006; Zoidl et al., 2007). In this study, we apply wide
field mosaic imaging to examine Panx1 expression in the rat brain
across four distinct regions that include cerebellum, hippocam-
pus, and cortex, olfactory bulb, and thalamus while still retaining
high spatial resolution. We compared the labeling patterns of four
different Panx1 antibodies in rat brain tissue in addition to model
cell culture systems using Western blot analysis, and immunocy-
tochemistry. Three of these antibodies are polyclonal antibodies
(one raised in rabbit and two in chicken) while the fourth is a
mouse monoclonal antibody. Two of these antibodies, one from
Diatheva and the other developed and validated in Gerhard Dahl’s
laboratory, have been used in several publications (described in
more detail in the Results section) while two were developed
and validated by our laboratory. The three polyclonal antibod-
ies show fairly similar neuronal labeling patterns across the four
brain regions while the Mo503 monoclonal antibody also labeled
the same neurons, but with different subcellular localizations. The
four antibodies recognize four different epitopes across the pro-
tein (Figure 1). In tissue culture cells, we found that both the
immunofluorescence and Western blot labeling were highly sim-
ilar, however there are significant differences in Western blots of
tissue among these antibodies.
Because Western blots are frequently treated as “gold standard”
controls, especially when used in combination with KO mouse
models, there is the widely held opinion that Western blot bands
ultimately determine specificity. A recent publication exempli-
fies this debate by showing that (1) numerous antibodies pass
all tests of specificity except the final test in KO mouse tissue,
FIGURE 1 | Diagram of Panx1 topology marked with the epitopes for
four different anti-Panx1 antibodies. Anti-Panx1 antibodies recognize the
Panx1 protein at different epitopes (Red – Mouse monoclonal 503
anti-Panx1 (Mo503), Blue – Chicken polyclonal Diatheva ANT0027 (CkDia)
anti-Panx1, Yellow – Rabbit polyclonal 57 (Rb57) anti-Panx1,
Green – Chicken polyclonal 4515 (Ck4515) anti-Panx1). The extracellular
loops of Panx1 contain four cysteine residues (magenta) as well as a
glycosylation site at N254. A schematized diagram of the carbohydrate tree
is indicated at this position. Caspase cleavage sites are located at residues
164–167 (Chekeni et al., 2010; site A) and 376–379 (Chekeni et al., 2010; site
B) and have been shown to be responsive to Casp3 and Casp7.
(2) some antibodies pass all tests of specificity by Western blot,
but not when using brain tissue, and (3) numerous antibodies
pass all rigorous tests of specificity by Western blot, but fail when
used for immunohistochemistry (Herkenham et al., 2011), caus-
ing the authors to re-assess the results in previous publications
that used those antibodies. In the case of pannexins, immunola-
beling results have been unclear and controversial. For example,
in the study of Panx1 knockout mice by Bargiotas et al. (2011)
where in situ hybridization images of Panx1 KO brain tissue were
devoid of staining for Panx1 transcripts, the authors state that
only one antibody (Penuela et al., 2007) out of six tested showed
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specificity for Panx1 in Western blot of their knockout animals.
The Diatheva and Dahl antibodies were two of the five the authors
claim to be non-specific. It has always been the case that specificity
of antibodies, particularly when used on intact tissues, is hard if
not impossible to prove. By these criteria, the results obtained in
Western blots in the present study should cause us to discard our
findings. However, it should be pointed out that the extra bands we
see on Westerns of tissue lysates may represent cellular constituents
present at the more complex tissue level that are unfolded on SDS
gels. These unfolded proteins may expose amino acid sequences
similar to the epitopes used to generate antibodies that are not
accessible in intact tissue with folded proteins and not present in
simpler cultured cells. This may be especially true since most anti-
bodies these days are generated by short peptides and not folded
proteins. We previously showed that connexin antibodies gener-
ated against the same C-terminal peptide are highly conformation
dependent (Sosinsky et al., 2007).
Here, we advocate for a more balanced approach where we
compare all data (Western blots and images from several anti-
bodies) to each other to look for conserved and variable features.
We believe that consistency among imaging and cell culture con-
trols with recombinant proteins are also important for antibody
validation. Tests of these antibodies on tissue lysates from two
different Panx1 KO mice demonstrate that they recognize Panx1
bands, however additional bands are labeled in the KO for some
of the antibodies and these vary between KO animals. Thus, it is
still unclear whether differences seen between the four antibodies
are due to different epitopes being recognized, non-specificity, or
the presence of some residual Panx1 protein in KO tissues. Nev-
ertheless, scientific papers continue to be published with these
antibodies and/or these KO mouse models, so we discuss strate-
gies for publishing this kind of data by recommending several
standards.
MATERIALS AND METHODS
ANTIBODY INFORMATION
For immunofluorescence experiments, we used either goat anti-
Myc (Abcam, Catalog# ab19234, Cambridge, MA, USA) or mouse
anti-Myc (Abcam, Catalog# ab32, Cambridge, MA, USA) for co-
labeling with either mouse monoclonal anti-Panx1 or rabbit poly-
clonal anti-Panx1 antibodies, respectively. Both antibodies were
used at a 1:250 dilution. GFAP, an astrocytic marker, was labeled
using a Guinea pig anti-GFAP (Advanced ImmunoChemical Inc.,
Long Beach, CA, USA) at a 1:800 dilution.
The four Panx1 antibodies used in this study were (1) a
commercial chicken anti-Panx1 (Diatheva ANT0027, denoted
as CkDia, Diatheva, Fano, Italy; NIF antibody registry number:
AB_10013320), (2) chicken anti-Panx1 (obtained from Gerhard
Dahl, University of Miami and denoted as Ck4515; NIF antibody
registry number: AB_10013321), (3) rabbit anti-Panx1 (denoted
as Rb57 ; NIF antibody registry number: AB_10013322), and (4)
mouse anti-Panx1 (denoted as Mo503; NIF antibody registry num-
ber: AB_10013323). All antibodies were affinity purified using
standard procedures.
(1) CkDia: chicken polyclonal antibody CkDia generated against
a peptide containing amino acids corresponding to 135–165 of
the cytoplasmic loop of the mouse Pannexin1. This antibody
was previously characterized in mouse brain by Zappala et al.
(2006).
(2) Ck4515: chicken polyclonal anti-human Panx1 antibody
(#4515, a gift from Dr. Gerhard Dahl at the University of
Miami Medical School) raised against a peptide containing
the most C-terminal amino acid residues (EKNSRQRLLNPS)
in the human Panx1 sequence (Locovei et al., 2006a) and
shows cross-reactivity between rat, mouse, and human Panx1
(Boassa et al., 2007).
(3) Rb57: rabbit polyclonal antibody Rb57 generated for our labo-
ratory by Abgent, Inc. (San Diego, CA, USA) against a peptide
containing amino acids 148–164 (KVYNRAIKAAKSARDLD)
of the first intracellular loop. This sequence is invariant among
mouse, rat, and human sequences.
(4) Mo503: monoclonal antibody Mo503 generated by Abgent,
Inc. (San Diego, CA, USA) for our laboratory against a pep-
tide containing amino acids 17–31 (LKEPTEPKFKGLRLE)
of the N-terminus of Panx1 and denoted as Mo503.
This sequence is invariant among mouse, rat, and human
sequences.
The characterization of the Laird laboratory antibody, denoted
RbCT-395, is described in Penuela et al. (2007). Its epitope is at
residues 395–409 (QRVEFKDLDLSSEAA) of mouse Panx1 and is
just upstream of the end of the C-terminus.
CELL CULTURE AND IMMUNOCYTOCHEMISTRY
HeLa cells (ATCC Catalog #CCL-2, Manassas, VA, USA) were cul-
tured in Cellgro DMEM (Mediatech, Inc., Manassas, VA, USA)
medium supplemented with 10% FBS in a 37˚C incubator with
10% CO2. Transient transfections were carried out using 2 mL
of Lipofectamine reagent (Invitrogen, Carlsbad, CA, USA) and
0.5 mg of DNA encoding Panx1-myc fusion protein in a pRK5 plas-
mid (Bruzzone et al., 2003). This transfection mixture was added
into each cell culture well containing 2 mL of medium and allowed
to incubate with cells for 2–4 h. The transfection medium was
removed and replaced with regular growth medium. Transfected
cells were allowed to continue growing for 24–48 h after transfec-
tion then fixed and prepared for fluorescent imaging. Coverslips
with transfected HeLa cells were fixed in 4% paraformaldehyde for
20 min at room temperature (CkDia and Ck4515) or fixed with
ice cold 100% methanol for 10 min then rinsed into PBS to rehy-
drate (Rb57 and Mo503). The different fixation methods were used
because while the CkDia, Ck4515, and Mo503 nicely label Panx1 in
tissue culture cells and brain tissue using 2–4% paraformaldehyde,
in these dual labeling experiments, the goat anti-Myc antibod-
ies gave significant background with paraformaldehyde fixation.
For these experiments, anti-Panx1 antibodies were used at 1:250
dilutions with an overnight incubation at 4ºC, and all secondary
antibodies were used at 1:100 for 1–2 h at room temperature.
The cells were briefly permeabilized with 0.1% Triton X100, then
blocked with 1% BSA, 3% normal donkey serum, 50 mM glycine,
and cold water fish gelatin in PBS. A summary of conditions for
each of these antibodies is shown in Table 1. For fluorescence
visualization, FITC and Cy5 conjugated donkey secondary anti-
bodies were used (Jackson ImmunoResearch Laboratories, Inc.,
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Table 1 | Summary of labeling information for the four Panx1 antibodies used in this analysis.
Panx1 antibody Source Catalog # Antibody ID# Cell fixation Tissue fixation Antigen retrieval
CkDia Diatheva ANT0027 AB_10013320 2% PFA or MeOH 4% PFA No
Ck4515 Laboratory of G. Dahl AB_10013321 2% PFA or MeOH 4% PFA No
Rb57 This lab AB_10013322 MeOH 4% PFA Yes
Mo503 This lab AB_10013323 2% PFA or MeOH 4% PFA No
Various conditions were utilized to achieve performance with each antibody in the applications presented in this body of work. PFA, paraformaldehyde; MeOH, cold
methanol. Use this table to quickly reference these differences in specimen preparation with the unique NIF antibody ID (Neuroscience Information Framework
Antibody Identifier http://antibodyregistry.org/antibody17/antibodyform.html?gui_type= advanced).
West Grove, PA, USA). Confocal images stacks were obtained
using an Olympus Fluoview 1000 microscope (Olympus USA,
PA, USA).
PREPARATION OF RAT BRAIN TISSUE AND IMMUNOHISTOCHEMISTRY
All experiments involving vertebrate animals conform to the
National Institutes of Health Guide for the Care and Use of Lab-
oratory Animals and were approved by the Institutional Animal
Care and Use Committee of the University of California San
Diego. The animal welfare assurance number is A3033-01. Rats
were fully anesthetized and Ringer’s solution containing xylo-
caine and heparin was perfused transcardially for 3 min followed
by 4% paraformaldehyde for 10 min. Here, we show images
obtained from an 8-week-old female Sprague-Dawley, however,
mosaic images from other rat brains we examined had the same
Panx1 patterns. The brain was removed and post-fixed in 4%
paraformaldehyde overnight at 4˚C. Sagittal sections were cut on a
Leica vibratome at a thickness of 75 microns and stored at−20˚C
in cryoprotectant solution (30% glycerol, 30% ethylene glycol in
PBS) until processed.
Before immunolabeling, each sagittal section was severed into
the four regions to be imaged (cerebellum, thalamus, olfac-
tory bulb, and hippocampus) to facilitate optimal flatness when
mounting on slides for subsequent wide scale imaging. Tissue
sections to be labeled with the Rb57 anti-Panx1 antibody under-
went antigen retrieval using heat and 10 mM citric acid pH 6.5
for 10 min (100˚C water bath in microwave oven; von Wasielewski
et al., 1994). Free-floating tissue sections were blocked with 3%
normal donkey serum, 1% bovine serum albumin, 1% cold water
fish gelatin, 0.1% Triton X100, and 50 mM glycine in PBS for 1 h
at room temperature. Guinea pig anti-GFAP and anti-Panx1 pri-
mary antibodies were applied overnight at 4˚C. FITC and Cy5 or
FITC and Rhodamine RedX conjugated donkey secondary anti-
bodies (Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA, USA) were applied for 2.5 h at room temperature. The Mo503
primary antibody was detected using a Rhodamine RedX con-
jugated donkey anti-mouse secondary antibody having minimal
cross-reaction to rat in order to avoid detection of endogenous rat
immunoglobulin in the tissue (Jackson ImmunoResearch Labo-
ratories, Inc., Catalog# 715-295-151). The immunolabeled tissue
samples were incubated with 0.5µM DAPI nuclear stain (Invit-
rogen, Carlsbad, CA, USA) for 20 min at room temperature and
carefully mounted as flat as possible using gelvatol as the mounting
medium.
WESTERN BLOTS
Lysates were prepared from MDCK cells stably over-expressing
Panx1 in addition to endogenous Panx1 as previously described
(Boassa et al., 2007; Ambrosi et al., 2010). Normal rodent brain
lysates were obtained from G-Biosciences (Maryland Heights, MO;
GenLysate Protein lysates of normal rat brain NLR-02, and nor-
mal mouse brain NLM-02). Normal rodent brain lysates were also
obtained from Enzo Life Sciences, Inc. (Farmingdale, NY, USA).
These included mouse brain lysates, Immunoblotting Standard
SW-104, and rat brain lysates, Immunoblotting Standard SW-
103. Proteins in the lysates were separated by SDS-PAGE on a
4–20% pre-cast gel (Invitrogen, Carlsbad, CA, USA). Proteins were
transferred to PVDF membrane (Millipore, Billerica, MA, USA),
using NuPAGE transfer buffer (Invitrogen). Bands on Western
blots were identified using the four anti-Panx1 antibodies with
HRP-conjugated secondary antibodies (Calbiochem); the chemi-
luminescence reaction was visualized using SuperSignal West Pico
ECL (Thermo Scientific,Waltham,MA,USA) and Kodak Gel Logic
2200 gel visualizer (Carestream Health, Inc., Rochester, NY, USA)
or X-ray film. The Mo503 and Rb57 antibodies were used at a
1:5000 dilution in blocking solution (1X PBS-T with 5% milk).
The Ck4515 and CkDia antibodies were diluted 1:2000 in a block-
ing solution made with 2% milk and 0.5 M NaCl in 1X PBS-T. This
stringent condition significantly reduced the background of these
two antibodies.
Lysates from matched Panx1 wild type and KO tissues were gen-
erated from animals from Genentech (Qu et al., 2011) and KOMP
(Qiu et al., 2011; Santiago et al., 2011). Methods for the prepa-
ration of tissues lysates and Western blots for the KOMP KO are
described in (Santiago et al., 2011). General methods for prepara-
tion of tissue lysates from the Genentech animals were prepared
using methods as described in Penuela et al. (2007).
WIDE SCALE FLUORESCENT IMAGING
Overlapping 3D image stacks were acquired with an Olympus
FluoView 1000 laser scanning confocal microscope equipped with
a 40×, NA 1.3, oil-immersion objective lens, and a special x, y, z
montaging stage. A multi-area time-lapse was performed using the
Olympus ASW1.7 software to define the boundaries of the tissue
area for the acquisition volume. The individual tiles of the montage
were acquired as z stacks of 4–6 sections (∼0.5–0.7 mm/section)
using sequential line scanning and then a maximum intensity pro-
jection of each stack is computed to make the individual tiles. The
tiles were stitched together post-data acquisition using National
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Center for Microscopy and Imaging Research (NCMIR) devel-
oped ImageJ plugins to project, flat field, normalize, align, and
combine into a mosaic (Chow et al., 2006; Kenyon et al., 2010).
Software is available for download1. The resulting reconstructed
mosaic image was downloaded and opened in Photoshop (Adobe
Systems Inc., San Jose, CA, USA) to rotate, crop, and adjust color
balance of the image.
IMAGE DEPOSITION INTO THE CELL CENTERED DATABASE
Mosaic images were acquired using an automated imaging work-
flow system developed at NCMIR to upload imaging data with
its associated metadata directly from the microscopes in our facil-
ity and register them as microscopy products within the CCDB
(Bouwer et al., 2011). This complex system for data collection, stor-
age, and manipulation funnels large numbers of valuable datasets
directly into the CCDB (Martone et al., 2008). Eighteen datasets
resulting from this publication have been released to the public
through the CCDB. Our large scale mosaics can be browsed or
downloaded through the Cell Centered Database (CCDB; Mar-
tone et al., 2002, 2008) at http://ccdb.ucsd.edu by selecting project
ID P20002. Because these data sets are quite large and rich in
information, each of these reconstructed mosaic images (usually
1–4 GB in size) is viewable at full resolution and annotatable
without downloading using the Web Image Browser (WIB2), a
visualization program based on GIS technology similar to that
used for Google maps, but specialized for microscopy imaging
data. Through the WIB, users can turn on and off channels and
adjust contrast of large microscopic imaging data sets.
RESULTS
This work focuses on the characterization of four different anti-
Panx1 antibodies in selected areas of the rat brain and compares
cellular localizations. In our study, we ask the question: “What are
the similarities and differences in tissue labeling patterns between
four antibodies generated against different parts of the same mol-
ecule?” The diagram in Figure 1 shows the topology of the Panx1
monomer and the epitopes of the four anti-Panx1 antibodies
examined. Common features provide clues as to how Panx1 is
localized to cellular sub-types, while dissimilar labeling may pro-
vide information about possible differences between neurons or
microenvironments in one area of the brain versus another. It is
difficult to point to which antibody is specific or non-specific as the
Rb57 antibody produces the most bands in a Western blot,however
the overall pattern of labeled cells in brain tissue matches that of
the Ck4515 and CkDia with the exception of cells lining the vessels
that are not labeled by Ck4515. As noted previously, epitopes are
highly conformation dependent and accessibilities may be differ-
ent in tissues where proteins are folded as opposed to Western blots
were proteins are unfolded. Incubation of the peptide used for gen-
erating Rb57 antibody eliminated immunofluorescence staining in
canine cardiac tissue (Dolmatova et al., 2012). Differences in the
labeling patterns may also indicate non-specific interactions of the
antibody that can occur due to recognition of similar short amino
acid sequences. For Panx1, this has been especially problematic
1https://confluence.crbs.ucsd.edu/display/ncmir/Mosaic+Plugins+for+ImageJ
2http://openccdb.org/software/index.shtm
(Bargiotas et al., 2011) indicating unanticipated complexity when
comparing simple tissue culture systems with intact tissue. Two
of these antibodies have already been characterized in publica-
tions (CkDia and Ck4515), while the other two were developed
by us using a contracted company and validated within our own
laboratory. The specificity of the Ck4515 anti-Panx1 antibody
was characterized in a previous publication by Western blot and
immunofluorescence staining in oocytes, erythrocytes and heart
capillaries (Locovei et al., 2006a). While not explicitly stated in
Locovei et al. (2006a), the Ck4515 antibody was validated for speci-
ficity in exogenously expressing oocytes using peptide competition
experiments and incubation with preimmune serum (Gerhard
Dahl, personal communication). This antibody was reported to
show no immunofluorescence in staining of Panx1 KO mouse
tissue (Zoidl et al., 2007) and has been used with several tissues
(Ransford et al., 2009; Silverman et al., 2009; Dolmatova et al.,
2012). The specificity of CkDia antibody was originally character-
ized in mouse brain and in transfect cells by Zappala et al. (2006)
who demonstrated a single band on Western blot that was absent
in parental HeLa cell lysate and eliminated by preabsorbing the
antibody with the immunizing antigen. CkDia has been used in
several publications (Romanov et al., 2007; Tang et al., 2008; Zhang
et al., 2008; Huang et al., 2011).
However, none of these antibodies has been compared to each
other using the same specimens and controls. As part of these
controls, we present Western blot data on Panx1 KO mice tissues.
It should be noted that while Panx1 labeling with recombinant
Panx1 in cultured cells gave consistent results, the Western blots
from KO animals were not entirely clean or consistent between
tissues and/or KO mice.
PANX1 LABELING IN CULTURED CELLS
Each of these four antibodies was first tested using transfected
Panx1-myc HeLa cells, a system where there is no endogenous
Panx1, to ensure that the antibody labeled exogenously expressed
tagged Panx1 (e.g., myc, Flag, His etc.), and showed almost com-
plete overlap with an antibody for the epitope tag. For immuno-
fluorescence experiments, HeLa cells transiently transfected with
Panx1-myc demonstrated the specificity of each of the four anti-
Panx1 antibodies based on the overlap of Panx1 with commercial
and well-characterized myc antibodies (Figure 2). A negative
control omitting primary antibodies from the initial incubation
showed no labeling (unpublished results). In addition, no staining
corresponding to the glycosylated or unglycosylated Panx1 bands
were obtained in Western blots of parental HeLa cell lysates for
these four antibodies (data not shown; Zappala et al., 2006). These
four anti-Panx1 antibodies performed similarly in labeling cul-
tured cells. Figure 2 shows that in non-expressing cells there is
typically little or no fluorescence. Co-localization of the labeling
pattern between Panx1 protein (grayscale, column1) and the myc
tag (grayscale, column2) resulted in yellow in the merged RGB
image (column 3) that showed expression at the cell membrane
as well as in intracellular populations, as has been previously pub-
lished (Boassa et al., 2007; Penuela et al., 2007; Boassa et al., 2008;
Penuela et al., 2009). The CkDia Panx1 antibody displayed some
low-level background fluorescence in non-transfected cells when
compared to the myc labeling, that is not present with the other
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three antibodies. These antibodies were also tested for immuno-
fluorescence with transfected HEK 293T cells, and MDCK cells
over-expressing Panx1 and showed the same overlapping labeling
patterns (unpublished results).
We used over-expressing Panx1 MDCK cells containing both
endogenous Panx1 and exogenous untagged Panx1 for our West-
ern blot analysis (Figure 2 right hand column). These cells
provided a very strong signal for detecting Panx1 in Western
blots and have two strong bands ∼48 and ∼52 kDa in size that
are labeled by all four antibodies. It has been previously estab-
lished that Panx1 in SDS-PAGE/Western Blots runs as three bands
that are correlated with their glycosylation status (Boassa et al.,
2007; Penuela et al., 2007). The Western blot in Figure 3 far
left panel shows that the lower band in Figure 2 was resolved
into two bands using a different lysate of the same cell line. This
pattern of three bands was evident with each of the four anti-
bodies tested (unpublished results). We have previously named
these three bands as GLY0 (non-glycosylated, bottom band), GLY1
(partially glycosylated, middle band), and GLY2 (fully glycosy-
lated, upper band). Our previous analyses (Boassa et al., 2007,
2008) and that of others (Penuela et al., 2007) demonstrated
that the fully glycosylated GLY2 Panx1 species localized to the
plasma membrane while the GLY0 and GLY1 Panx1 species are
found in intracellular compartments. It should be noted that
parental MDCK cells containing only endogenous Panx1 show
a similar profile, but the GLY0, GLY1, and GLY2 bands have
weaker intensities consistent with less expression (Penuela et al.,
2007). These Panx1 protein bands were used to compare for
molecular weights with endogenous Panx1 found in brain tissue
(Figure 3).
WESTERN BLOT LABELING OF BRAIN TISSUE
While model cultured cells represent excellent homogeneous and
easily manipulated systems for understanding expression and traf-
ficking, we focused our study on expression patterns of Panx1 in
the more complex organization of brain tissue, a heterogeneous
organ containing several cell types intermingled and interact-
ing within spatial domains. We originally tested Western blots of
commercially available rat and mouse brain lysates with all four
antibodies (data not shown). We analyzed the rodent brain lysates
after SDS-PAGE and Western blotting and the Panx1 banding pat-
terns comparing rat to mouse brain were similar. Although each
of the four antibodies gave highly similar banding patterns in tis-
sue culture cells, there were variations in the banding patterns in
Westerns of the same rat and mouse brain lysates using these four
Panx1 antibodies. We also performed Western blots of rat cerebel-
lum lysates, however the banding pattern for each antibody looked
the same as the total rat brain lysates.
As additional controls for validating our antibodies using West-
ern blots, we analyzed banding patterns between wild type and
KO mice generated independently by two different labs (Qu et al.,
2011; Santiago et al., 2011). Contrary to what has been reported by
Bargiotas et al. (2011), we see a reduction or elimination of bands
in the 36–55 kDa region of expected Panx1 bands (see bracketed
region indicated in the far left Western) of the KO tissue with all
antibodies. However, we also saw bands in the∼20 kDa range that
also were eliminated or decreased. Residual weak bands in the KO
lanes may be a result of incomplete knock-down of the Panx1
protein in these two knockout models. Every antibody tested, even
CT-395 (which Bargiotas et al. stated was the one successful anti-
body to show knockout of Panx1), showed additional bands that
are not eliminated or reduced in a KO tissue. As an example,
the Mo503 antibody showed a much more dramatic reduction
in spleen (Figure 3B) than in brain KO tissues (Figure 3C). Addi-
tionally, the 64 kDa bands in the spleen lysate of the Genentech
KO mouse were not present in the brain lysates of the KOMP KO
mouse. Particularly, while the CT-395 antibody Western blot in
Figure 3 does not show Panx1 bands in the knockout lane in this
figure, longer exposures of the Western blot show Panx1 bands in
the expected 36–55 kDa region (data not shown). Thus, we not
only saw differences between different antibodies, but also differ-
ences between KO models and even KO tissues from the same
animals. It is important to note that a quantitative real time poly-
merase chain reaction (qRT-PCR) analysis of Panx1 transcripts in
several tissues demonstrated that Panx1 knockout animals gen-
erated by KOMP using the knockout first strategy (Testa et al.,
2004) are hypomorphs rather than true knockouts (Hanstein et al.,
submitted).
PANX1 LABELING IN FOUR BRAIN REGIONS
We focused on cerebellum, hippocampus, olfactory bulb, and thal-
amus, four areas of the rat brain that have all been reported to have
high Panx1 expression using in situ hybridization in either mouse
or brain tissue (Ray et al., 2005; Vogt et al., 2005; Weickert et al.,
2005; Lein et al., 2007). Wide scale immunofluorescence mosaic
images allowed us to image large morphological domains while
still retaining labeling information at the cellular resolution scale.
Immunolabeled sagittal rat brain slices corresponding approxi-
mately to a lateral position of 1.40–2.10 mm of the Paxinos and
Watson (1998) rat brain atlas were imaged in four large regions
(Figures 4–9). In addition, the hippocampus and olfactory bulb
images contain areas of nearby neocortex. In Figures 4, 6, 7, and
9, we show only one montage using the CkDia antibody but also
show full resolution views from within montages of brain regions
labeled with each of the four antibodies. The Panx1 labeling is
always shown in green. Each tissue slice was also labeled with anti-
GFAP antibodies to distinguish astrocytes (red) while cell nuclei
were stained with DAPI (blue).
Because image data is rich in information and each montage at
full resolution is typically over 2 GB, we chose to make all mon-
tages publicly available, rather than show down-sampled mosaics,
except as an example for each area. Each of these mosaics at full res-
olution has been deposited in the CCDB under project ID P20002
and can be viewed using the Web Image Browser (WIB) or down-
loaded onto a reader’s computer via the CCDB portal3. Table 2
contains URLs linking to each of these large data sets for viewing
using the WIB.
Cerebellum
Examples of the cerebellar cell types labeled by the anti-Panx1
antibodies are shown in Figures 4 and 5. These include Purkinje
3http://ccdb.ucsd.edu
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FIGURE 2 | Anti-Panx1 and anti-myc antibodies recognize Panx1-myc
transiently expressed in HeLa cells. From left to right, each row of images
shows anti-Panx1, anti-myc, and a color overlay of the previous two images
with Panx1 in green, myc in red, and DAPI in blue, followed by the
corresponding DIC image. Note the overlap of the Panx1 and myc staining
and the lack of signal in untransfected cells. Each of these antibodies against
Panx1 decorates the plasma membrane as well as intracellular localization. A
Western blot for Panx1 in cell lysates prepared from over-expressed Panx1
stably expressed in MDCK cells for each of these antibodies is shown in the
right hand column.
FIGURE 3 | Western blot analysis of Panx1 protein in cell and brain
lysates probed with four different anti-Panx1 antibodies. (A) Banding
pattern of MDCK lysates at the far left, glycosylation bands are noted as:
GLY0, GLY1, GLY2. (B) Tissue lysates from either brain or spleen from the
Genentech generated KO mouse are examined by Western blot with the
four antibodies used for imaging studies. The bracket at left highlights the
∼43–55 kDa region where bands for Panx1 species are expected and
show decreases in the KO tissue. The Western blot at the far right uses
the CT-395 antibody developed by the Laird laboratory and serves as a
control for matching against our antibodies. α-tubulin blots are shown as a
loading control. (C) Cerebellum and hippocampus tissue lysates from a
KOMP generated Panx1 KO show decreased intensity from wild type in
Western blots. Here, Western blotting against GAPDH was used as a
loading control.
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FIGURE 4 | Large scale mosaic imaging of rat brain cerebellum. Top: this
representative cerebellum montage is labeled with CkDia anti-Panx1 antibody
(green), GFAP (red), and DAPI (blue, nuclei). This mosaic image is made up of
587 tiles. Each tile is a maximum intensity projection of a stack of five
Z-sections that were stitched together to reconstruct this single,
high-resolution 2D image. Bottom: full resolution views of cerebellar regions
and cell types labeled by the four anti-Panx1 antibodies. Arrowheads in the
Mo503 left hand image= stellate cells.
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FIGURE 5 | Cerebellar cell types labeled by Rb57 anti-Panx1
antibody. Labeling of rat cerebellum tissue with the Rb57
anti-Panx1 antibody reveals expression in Purkinje neurons (white
arrowheads), Golgi cells within the granular layer (white arrows),
Bergmann glia within the molecular layer of the cerebellum (yellow
arrowheads), and additional cell bodies in the molecular layer that
may be stellate cells. (A) Merged image (B) Panx1 channel shown
in grayscale.
neurons, Golgi neurons, Bergman glia, and their parent cells, the
Golgi epithelial cells, as well as cells within the deep cerebellar
nuclei, all of which have been previously reported to contain
significant amounts of Panx1 in mouse brain (Ray et al., 2006;
Zappala et al., 2006). In comparing the staining patterns of these
four antibodies (Figure 4, bottom), some patterns of differen-
tial antibody labeling across cerebellum tissue became apparent.
For example, we found that the Mo503 antibody labels stellate
cells or basket cells of the molecular layer (Figure 4, white arrow-
heads). The Rb57 antibody labeled cell bodies within the white
matter while the CkDia antibody labels astrocytes within the white
matter (Figure 4, bottom column 6). The three polyclonal anti-
bodies labeled the Bergman glia; however no glial staining was
observed with the Mo503 anti-Panx1 antibody (Figure 4, bottom,
column 2). In Purkinje neurons, the labeling of all four antibod-
ies was localized to the cell bodies, however, some staining of the
axonal processes were visible, especially with the Mo503 antibody.
The choroid plexus subcellular distribution was more speckled
although some hints of apparent plasma membrane staining can
be seen using the CkDia antibody. In the higher magnification
view shown in Figure 5, labeling of rat cerebellum tissue with the
Rb57 anti-Panx1 antibody revealed expression in Purkinje neurons
(white arrowheads), Bergmann glia within the molecular layer
of the cerebellum (yellow arrowheads), as well as Golgi neurons
within the granular layer (white arrows). In general, all three poly-
clonal antibodies labeled Panx1 in astrocytes in the cerebellum.
This overlap was more obvious when viewing the image through
the WIB and the red GFAP channel was turned off.
Hippocampus
Examples of hippocampal cell types (and neocortex lying super-
ficial to the hippocampus) labeled by the anti-Panx1 anti-
bodies are shown in Figures 6 and 7. These images contain
pyramidal neurons and astrocytes that have been previously
reported to express Panx1 at the protein level in mouse brain
(Zappala et al., 2006; Zappala et al., 2007; Karpuk et al., 2011).Ves-
sel labeling by CkDia and Rb57 antibodies was difficult to
distinguish from astrocyte end feet that are wrapped around
the vessels and highly labeled in this brain region. Interestingly,
even in instances where all four antibodies label the same cell
type in consensus, like in the pyramidal neurons of the hip-
pocampus (Figure 6), there were still differences at the subcel-
lular level. In this case, the three polyclonal anti-Panx1 anti-
bodies label the cell body and adjacent portion of the apical
dendrite, while the Mo503 anti-Panx1 labeling is restricted to
the dendrites of these cells (Figure 7). In many cell types the
Mo503 preferentially labels dendrites or other cellular exten-
sions and weakly labels cell bodies such as in the hippocampal
pyramidal neurons and pyramidal cells of the neocortex region,
while the polyclonal antibodies often highlight the cell bodies
(Figures 4 and 6–9). Astrocytes in this region were labeled with
the three polyclonal antibodies, but not by the monoclonal Mo503
antibody.
Olfactory Bulb
The anti-Panx1 antibodies shown in Figure 8 labeled several
olfactory bulb cell types. These include the mitral cells, cells
within the glomeruli of the main olfactory bulb (MOB) and
cells within the exterior plexiform layer of the accessory olfac-
tory bulb (AOB), and cells of the adjacent neocortex. In the
examples of blood vessels from this region the Rb57 antibody
sporadically labels cells lining the vessels, presumptively endothe-
lial cells (Figure 8, bottom, column 3). Panx1 immunostaining
has been previously reported in strial blood vessels in the cochlea
(Wang et al., 2009) and in the endothelial cells of cardiac cap-
illaries (Locovei et al., 2006a) using the Ck4515 antibody and
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FIGURE 6 | Large scale mosaic imaging of hippocampus and neocortex
lying adjacent to the hipps ocampus. Top: this Representative
hippocampus montage is labeled with CkDia anti-Panx1 antibody (green),
GFAP (red), and counterstained nuclei with DAPI (blue). This mosaic image is
made up of 167 tiles. Each tile is a maximum intensity projection of a stack of
four Z-sections that were stitched together to reconstruct this single,
high-resolution 2D image. Bottom: full resolution views of hippocampal
regions and cell types labeled by the four anti-Panx1 antibodies.
in endothelial cells of lens capillaries (Dvoriantchikova et al.,
2006b) using a different rabbit polyclonal antibody. Two red
blood cells that are quite rare with this type of specimen prepa-
ration can be seen clearly in this instance within the blood
vessel (white arrows), confirming robust Panx1 expression in
erythrocytes (Locovei et al., 2006a). Again, as shown in the
mitral cells, exterior plexiform layer, and neocortex, the poly-
clonal antibodies highlighted the neuronal cell bodies much more
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FIGURE 7 | Differential subcellular labeling of Panx1 in the dendate
gyrus of the rat hippocampus with combinations of four anti-Panx1
antibodies. Although the neurons of the hippocampus are a consensus
cell type labeled by all four of the Panx1 antibodies, there are differences
in the apparent subcellular localization of the protein population recognized
by each antibody. In these five panels, each antibody is shown in black and
white (middle and right hand images) and as a composite color image in
the left hand images. In all composite images, astrocytes are labeled with
anti-GFAP (blue). (A) Co-labeling with Ck4515 and Mo503. (B) Co-labeling
with Ck4515 and Rb57. (C) Co-labeling with Rb57 and Mo503. (D)
Co-labeling with CkDia and Mo503. (E) Co-labeling with Rb57 and CkDia.
Tissue slices labeled with Rb57 (B,C,E) underwent antigen retrieval prior
to immunolabeling. Co-labeling tissue with the polyclonal antibodies
reveals that these primarily highlight the cell body and the adjacent portion
of the dendrite however the Mo503 antibody (red) decorates the long
dendrites of these cells with less noticeable staining at the cell bodies.
However, there is a substantial degree of overlap in staining between all
the antibodies.
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FIGURE 8 | Large scale mosaic imaging of rat brain olfactory bulb
and neocortex lying adjacent to the olfactory bulb. Top:
representative montage labeled with CkDia anti-Panx1 antibody (green),
anti-GFAP (red), and DAPI (blue, nuclei). This mosaic image is made up of
649 tiles. Each tile is a maximum intensity projection of a stack of five
Z-sections that were stitched together to reconstruct this single,
high-resolution 2D image. Bottom: full resolution views of olfactory bulb
regions and cell types labeled by the four anti-Panx1 Abs. White
arrows= red blood cells, MOB, main olfactory bulb; AOB, accessory
olfactory bulb; NC, neocortex.
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FIGURE 9 | Large scale mosaic imaging of rat brain thalamus. Top:
representative thalamus montage labeled with CkDia anti-Panx1 (green),
anti-GFAP (red), and DAPI (blue, nucleus). This mosaic image is made up of
447 tiles. Each tile is a maximum intensity projection of a stack of five
Z-sections that were stitched together to reconstruct this single,
high-resolution 2D image. Bottom: full resolution views of thalamus regions
labeled by the four anti-Panx1 antibodies.
than the Mo503 antibody that preferentially stained the neuronal
processes.
Thalamus
Previous in situ hybridization studies showed staining with Panx1
mRNA probes in the mouse thalamus and in particular, reticular
thalamic neurons (Ray et al., 2005). We found in this tissue, Panx1
localized mostly to neuronal cell bodies, although the Mo503 and
Ck4515 do delineate neuronal processes. As with the other brain
regions, the Rb57 and CkDia antibodies recognize sporadic cells
lining blood vessels, presumably endothelial cells, while the other
two do not (Figure 9). Interestingly, this brain region had the
least labeling of Panx1 in astrocytes. It has been shown previously
that astrocytes cultured from specific brain regions show differen-
tial expression patterns of adrenergic receptors (Ernsberger et al.,
1990) and the differing astrocytic labeling we see in the various
brain regions could be attributed to this phenomenon.
DISCUSSION
Panx1 is the most studied and best characterized isoform of the
pannexin protein family. It has been demonstrated to form large
conductance channels in neurons, glial cells, and erythrocytes
(Locovei et al., 2006a; Thompson et al., 2008; Iglesias et al., 2009).
The opening of Panx1 channels has been induced by various exper-
imental conditions, including activation of purinergic receptors,
stretch, high intracellular calcium, and membrane depolarization
(Bao et al., 2004; Locovei et al., 2006b; Pelegrin and Surprenant,
2006). Panx1 is insensitive to variations in extracellular calcium
concentrations over a wide range (Bruzzone et al., 2005) and
opens at negative resting potential in response to mechanical stress
and at micromolar increase of intracellular calcium (Bao et al.,
2004; Locovei et al., 2006a). In conjunction with the sensitivity
of Panx1 to extracellular ATP through purinergic receptors of the
P2Y and P2X type (Locovei et al., 2007), it has been postulated
that a prime function of Panx1 channels are as ATP release con-
duits mediating extracellular propagation of Ca2+ waves (Locovei
et al., 2006a,b). Astrocytes propagate Ca2+ waves (Cornell-Bell
et al., 1990; Arcuino et al., 2002) and have been suggested to be
an important mechanism in neuronal – glial signal transmission
(Nedergaard et al., 2003; Newman, 2003; Volterra and Steinhauser,
2004).
It has been proposed that Panx1 channels are involved in path-
ways activated upon a strong stimulus, such as inflammation (Kan-
neganti et al., 2007; Silverman et al., 2009), ischemia (Thompson
et al., 2006), or myocardial infarction (Dolmatova et al., 2012). In
keeping with the hypothesis that Panx1 channels open only upon a
stimulus, Panx1 channels are constitutively closed (Bao et al., 2004;
Bruzzone et al., 2005). Panx1 channels (pannexons) lack sensitivity
to extracellular Ca2+, an important property, as Panx1 channels
will not be open under physiological ionic conditions. In neurons
and possibly astrocytes, Panx1 may contribute to novel forms of
synaptic and non-synaptic communication and Ca2+ wave prop-
agation (MacVicar and Thompson, 2010). In mammalian skin,
Panx1 plays a key role in keratinocyte differentiation. Furthermore,
in the cardiac, nervous, and immune systems, Panx1 activation
is implicated in ischemic, excitotoxic, and ATP-dependent cell
death such that Panx1 coupling with purinergic receptors triggers
an inflammasome mediated response (Kanneganti et al., 2007;
Pelegrin et al., 2008; Silverman et al., 2009). Reactive astrocytes
immediately bordering an abscess exhibited open Panx1 channels
during the acute inflammatory period, which dissipated as the
infection evolved (Karpuk et al., 2011). Additionally, P2X7 receptor
activation induces Panx1 channel opening in astrocytes (Scemes
et al., 2007; Iglesias et al., 2009; Suadicani et al., 2012). Panx1
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Table 2 | List of URLs linking to display of full resolution large-scale mosaic images using four different anti-Panx1 antibodies of four regions
within the rat brain studies here.
Brain region Panx1 Ab CCDB MP ID URL
Cerebellum CkDia 56630 http://purl.oclc.org/NET/56630_CkDia_Cer
Cerebellum (Alternate) CkDia 57185 http://purl.oclc.org/NET/57185_CkDia_Cer
Thalamus CkDia 48338 http://purl.oclc.org/NET/48338_CkDia_Thal
Thalamus (Alternate) CkDia 46648 http://purl.oclc.org/NET/46648_CkDia_Thal
Hippocampus CkDia 48367 http://purl.oclc.org/NET/48367_CkDia_Hip
Olfactory bulb CkDia 58640 http://purl.oclc.org/NET/58640_CkDia_Olf
Cerebellum Ck4515 44959 http://purl.oclc.org/NET/44959_Ck4515_Cer
Thalamus Ck4515 48920 http://purl.oclc.org/NET/48920_Ck4515_Thal
Hippocampus Ck4515 48902 http://purl.oclc.org/NET/48902_Ck4515_Hip
Olfactory bulb Ck4515 48664 http://purl.oclc.org/NET/48664_Ck4515_Olf
Cerebellum Mo503 45305 http://purl.oclc.org/NET/45305_Mo503_Cer
Thalamus Mo503 58721 http://purl.oclc.org/NET/58721_Mo503_Thal
Hippocampus Mo503 58445 http://purl.oclc.org/NET/58445_Mo503_Hip
Olfactory bulb Mo503 58675 http://purl.oclc.org/NET/58675_Mo503_Olf
Cerebellum Rb57 45276 http://purl.oclc.org/NET/45276_Rb57_Cer
Thalamus Rb57 59247 http://purl.oclc.org/NET/59247_Rb57_Thal
Hippocampus Rb57 56258 http://purl.oclc.org/NET/56258_Rb57_Hip
Olfactory bulb Rb57 58377 http://purl.oclc.org/NET/58377_Rb57_Olf
Eighteen full resolution montage images are viewable using the WIB tool by clicking on these URLs. Two high quality montages for which individual images are
not shown in the galleries in Figures 4–9 are also available for viewing and downloading and are denoted by “Alternate” under the brain region category. CkDia,
Chicken Diatheva ANT0027 polyclonal antibody; Ck4515, Chicken 4515 polyclonal antibody (Dahl laboratory); Rb57, Rabbit 57 polyclonal antibody (Sosinsky lab); Mouse
monoclonal 503 polyclonal antibody (Sosinsky lab). Each brain region is displayed with anterior facing left, and the reconstructed images have been cropped and color
balance adjusted using Photoshop. All images (raw and processed) as well as associated metadata can be downloaded through the CCDB using the listed microscopy
product identification number (MPID).
channel activity has been implicated recently in inflammasome
formation in cultured neurons and astrocytes (Silverman et al.,
2009). The latter data suggest a crucial role for Panx1 in several
cell death pathways in the nervous system (Bargiotas et al., 2009;
MacVicar and Thompson, 2010), although a recent Panx1 KO
mouse showed no morphological changes in brain slices by histo-
logical analysis or changes in IL-1β from macrophages (Bargiotas
et al., 2011). The authors stated in the on-line supporting infor-
mation that five out of six commonly used anti-Panx1 antibodies
tested on KO mouse tissue in Western blots were “non-specific,”
however no original data detailing protein specificity from these
Western blots or immunofluorescence imaging was provided. It is
possible that in actuality some tissues of that particular KO mouse
still contain Panx1 protein or again, Western blots are not the only
diagnostic to be trusted for Panxs.
GENERATING A PANX1 ANTIBODY TOOL-KIT
The four antibodies used in this study performed well in cell cul-
ture by labeling exogenous protein with an independent tag and
showed a consistent and similar banding pattern on Western blots.
In generating or testing antibodies against anti-Panx1 peptides, we
used several standard criteria for a “good” antibody. One quality
for a good Panx1 antibody generated was the ability to recog-
nize recombinant protein containing an appended independent
tag when expressed in tissue culture cells such that an antibody
against the tag overlapped with the Panx1 staining. As important,
was that the Panx1 labeling patterns in exogenously expressing
cultured cells would be similar to those found in endogenously
expressing Panx1 cells. In our case, endogenously expressing Panx1
cell staining was very similar to transfected cells (Boassa et al.,
2007). Another criterion was that in model systems, antibodies
would recognize recombinant protein and endogenous protein on
Western blots in a manner consistent with their expected mole-
cular size and/or post-translational modifications. As a negative
control, elimination of the primary antibody would abolish sig-
nal on Western blots of tissue culture cells and/or on tissue. For
recombinant Panx1 in cells, Western blots of parental cell lines
provide a critical negative control. We showed using Panx1 KO
mice as a negative control (Figures 3B,C) that these four anti-
bodies recognize Panx1 at its expected sizes as well as some sizes
that are not yet explainable. There are some non-specific bands
on some of the Western blots that do not disappear in the knock
out tissue lysates consistently, as they are only present in some
tissue samples. It is worth noting that Qiu et al. (2011) and San-
tiago et al. (2011) used the Ck4515 antibody to validate lack
of expression in a Panx1 KO. Notably, two recent publications
(Burns et al., 2012; Lohman et al., 2012) used immunoblotting,
immunohistochemistry, and RT-PCR methods to cross-validate
expression patterns in cerebral vasculature. However, it is impor-
tant to remember that RT-PCR methods assay for mRNA expres-
sion, which can be different from protein expression. For example,
Lohman et al. (2012) demonstrated that HEK293 cells, a cell line
that has been documented in several studies as being negative
for Panx1 expression, has residual Panx1 mRNA but no protein
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expression as assayed by Western blots and immunohistochemical
imaging.
This work focused on imaging Panx1 expression in select areas
of the rat brain and compared their cellular localizations. Although
Panx1 antibodies have been criticized for lack of specificity, this
comparative labeling study takes into account the differences
between antibody epitopes and labeling requirements and uti-
lizes their unique qualities. Uncertainty in the antibodies currently
available (both privately and commercially) is due to various rea-
sons. It is hard to find a single antibody that can perform well
by recognizing the Panx1 protein under all Western blot and
immuno-microscopy conditions, which has been shown for other
protein targets as well especially in brain tissue (Herkenham et al.,
2011). Another reason for uncertainty about Panx1 antibodies
has been the failure to fully characterize, at the protein level, the
original report of a Panx1 KO mouse that was generated sev-
eral years ago (Anselmi et al., 2008). Now additional Panx1 KO
mouse lines have been generated by various techniques and so far
they all perform differently under these rigorous tests by Western
blot. Because of this discrepancy and the difficulty in brain tissue
preservation, there are few published cellular level images of Panx1
protein expression in brain and all have limited fields of view (Ray
et al., 2006; Zappala et al., 2006; Zoidl et al., 2007; Karpuk et al.,
2011). We performed these experiments in rat brain because no
non-specific cross-reaction would occur due to labeling the same
species that the antibodies were generated against (a mouse against
mouse reaction).
COMPARISON OF PROTEIN LABELING TO IN SITU HYBRIDIZATION
STUDIES
The ability to combine gross structural imaging with high-
resolution microscopy on a large scale significantly advances our
ability to detect and analyze multiple brain regions. The trade-off
between resolution and field of view leads to targeted investiga-
tions limited to regions of the brain that are determined to be
heavily labeled and well studied while ignoring areas that may
be smaller or more subtly labeled. In situ hybridization provided
a first estimate of where pannexins are located (Baranova et al.,
2004; Vogt et al., 2005; Weickert et al., 2005). In situ hybridiza-
tion provides a first approach to assembling a protein expression
map in tissues because it is easier and faster to generate riboprobes
than antibodies. However, proteins in the nervous system can be
very far removed from where the genes are expressed; thus, in situ
hybridization investigations give only a limited view of expression
patterns. Correlation between the two types of staining can be dif-
ficult, because antibodies do not always label the protein in the cell
body, leading to difficulties in ascertaining the identity of labeled
axons and dendrites.
For the most part, our antibody labeling across brain domains
are similar to those obtained with in situ hybridization. Strong
staining has been observed in the cerebellum, hippocampus, olfac-
tory bulb, and thalamus (Ray et al., 2005; Vogt et al., 2005). In the
cerebellum (Vogt et al., 2005), found that all layers showed signal
but it was highest in Purkinje cells, Golgi cells, and deep cerebellar
nuclear cells. In the olfactory bulb, we found that the strongest sig-
nal was in the mitral cell layer and AOB. Vogt et al. (2005) showed
that some labeling occurred in the granule cell layer of the olfactory
bulb. The hippocampus contained high Panx1 expression in the
dentate gyrus and all CA regions, pyramidal cells, stratum oriens,
radiatum, and lacunosum-moleculare. (Vogt et al., 2005) found
that co-labeling with GFAP and NeuN antibodies with riboprobes
highlighted that neurons were labeled but astrocytes were not.
In particular, Vogt et al. (2005) found that GABAergic interneu-
rons and pyramidal neurons showed significant Panx1 staining. In
our study, we found that, while there were consistencies between
the four antibody labels, the subcellular distribution could vary as
shown in the pyramidal neurons of the hippocampus. We observed
Panx1 staining in astrocytes using all of the polyclonal antibodies
including CkDia, although initial characterization of this antibody
by Zappala et al. (2006) did not include descriptions of astrocytic
staining. It should be noted that Panx1 expression in astrocytes was
recently demonstrated in vivo both functionally and by immuno-
histochemistry (Karpuk et al., 2011; Santiago et al., 2011) and in
Western blot analysis of cultured astrocytes (Huang et al., 2007;
Iglesias et al., 2009; Silverman et al., 2009; Suadicani et al., 2012).
High Panx1 RNA expression was documented from staining of the
thalamic reticular nucleus (Ray et al., 2005), while we find protein
labeling of sporadic cells in this region with each antibody that
was used for staining.
CONSISTENT AND VARIABLE FEATURES BETWEEN THE FOUR
ANTIBODY LABELING PATTERNS
A major goal of this study was to determine subcellular patterns of
expression across the different brain regions and search for consis-
tent patterns between the four antibodies. Each of these antibodies
has a unique epitope with only two (CkDia and Rb57) of them
overlapping. As such, these two antibodies had similar domain and
subcellular labeling patterns, in that they tended to highlight the
neuronal cell bodies as well as astrocytes, and endothelial cells in
most of the brain regions we imaged. Some images are suggestive of
plasma membrane staining, particularly with the Mo503 antibody.
However, electron microscopy of these slices will be necessary
to unequivocally determine this, since it is sometimes difficult
to determine proteins or protein complexes that lie just under-
neath or within the plasma membrane. The Ck4515 antibody, a
very commonly used antibody within the pannexin field, has an
expression pattern that is closer to the CkDia and Rb57 labeling
patterns than the Mo503 labeling. Our results in hippocampus
with the Ck4515 antibody were similar to those of Santiago et al.
(2011) who used an antibody generated against the same peptide
as Ck4515 and showed labeling in neurons, astrocytes, and perivas-
cular astrocytic endfeet in hippocampal area CA1. That study also
showed no non-specific labeling in KO mouse tissue.
MODIFICATIONS TO PANX1 GENE EXPRESSION THAT COULD IMPACT
EXPRESSION PATTERNS
Other considerations in understanding, Panx1 labeling include
post-translational modifications or differentially translated Panx1
that could complicate various banding patterns that were unan-
ticipated from tissue culture control experiments. Using the same
tissue lysate, the Western blot protein patterns varied depending
on the antibody and presented a more complex situation than tis-
sue culture cells. Our Western blots of the same rat and mouse
brain lysates varied from two to eight major bands depending
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on the probing antibody. In other published studies, bands were
shown at ∼43,∼52, and ∼96 kDa in Western blots of mouse and
rat brain lysates (Wang et al., 2009) while five bands corresponding
in approximate size to exogenously expressed Panx1 protein were
recently shown in rat brain lysate by Western blot (Kienitz et al.,
2011).
Several factors may influence the number of bands seen on
Western blots. Glycosylation results in having multiple bands
although the number can range depending on the tissue and cell
type (Boassa et al., 2007; Penuela et al., 2007). Furthermore, these
glycosylated species were shown to give rise to spatial separation
of the fully glycosylated GLY2 in the plasma membrane and the
GLY0 and GLY1 isotypes in intracellular compartments such as the
ER. Recently, Panx1 has been shown to have two potential caspase
cleavage sites of which one site was cleaved by caspases 3 and 7
(Chekeni et al., 2010). Either of these two sites, cleaved separately
or in combination in brain tissue, would cause differential recog-
nition of the resulting protein by these four antibodies (Table 3,
see sites in Figure 1). Panx1 has also recently been shown to be
expressed as three additional splice variants in the pituitary gland
(Li et al., 2011) that would also give rise to differential recognition
of Panx1 species of 48 kDa by all antibodies for the full-length
(“Panx1a”splice variant), 40 kDa for Ck4515, and Mo503 antibod-
ies for the “Panx1c” splice variant or 35 kDa recognized by CkDia,
Rb57, and Mo503 for the “Panx1d” splice variant. In addition, it
is important to note that glycosylation of several of these Panx1
species will affect the experimentally measured monomer size if
the Panx1 species retains the N254 glycosylation site. Lastly, while
inhibitors of proteolytic enzymes are typically included in lysate
protocols and prevent gross damage, proteolytic cleavage may still
occur during the dissection and homogenization process.
The complex labeling patterns we see may be a reflection of
different cellular and subcellular localizations, where each anti-
body is highlighting unique subpopulations of accessible Panx1
epitopes of this dynamically expressed and processed protein. For
example, in many cell types the Mo503 antibody preferentially
labels dendrites and not cell bodies, while the other antibodies
often highlight the cell bodies. The mouse antibody is unique in
that it was generated against part of the N-terminus. Our tissue
labeling results are consistent with tissue culture systems where
Panx1 is localized to both the plasma membrane and intracellu-
lar membrane compartments. It is important to note that some
tissue culture cells such as bEnd3 vascular endothelial cells show
Table 3 | Differential recognition of predicted fragments resulting from
caspase cleavage of Panx1.
Ck4515 CkDia Rb57 Mo503
Full-length Panx1 48* 48* 48* 48*
Caspase site A cleavage 30* 18 18 18
Caspase site B cleavage 6 42* 42* 42*
Double caspase cleavage at both sites 6 18 18 18
These antibodies are predicted to recognize differently sized fragments
(expressed in kDa) of the Panx1 protein after caspase cleavage (see Figure 1
for schematic). *= fragment containing the N-glycosylation site.
only intracellular immunofluorescence that correlated with the
appearance of only the GLY0 band on Western blots (Boassa et al.,
2007). At the present time, we believe a more in-depth analysis of
Panx1 gene and protein modifications will be necessary to fully
interpret the bands we see on our Western blots.
NEUROINFORMATICS RESOURCES AND TOOLS FOR DECIPHERING
PANX1 PROTEIN EXPRESSION
Although we cannot conclusively establish localization of pan-
nexin protein because of the variability between antibodies, tissues,
and assay systems, we believe that this paper illustrates several best
practices that should be employed in all immunolabeling studies
to make it easier to compare findings and to ensure that problem-
atic information is not suppressed during the publication process,
but rather exposed so that the community has accurate informa-
tion (MacArthur, 2012). As a first step, we provided all identifying
information for each antibody (vendor, catalog#, clone ID, and
Antibody Registry URI). The Antibody Registry is a web resource
that issues a stable, traceable, permanent identifier for an anti-
body created by commercial vendors or individual labs so that a
researcher can easily find the antibody used in a scientific paper
and trace that antibody back to the creator. Often, manufactur-
ers have more than one antibody to the same protein, and it is
important that the catalog number be included for all reagents.
However, commercial vendor IDs may not be stable over time, as
vendors go out of business or sell their product lines. For this rea-
son, the Neuroscience Information Framework (NIF4), a project
designed to make it easier to identify resources of relevance to neu-
roscience (Gardner et al., 2008), created the Antibody Registry5.
The Antibody Registry currently contains >900,000 antibodies,
largely from commercial sources. Each is given its own unique
accession number, much like a gene sequence in GenBank that can
be used to uniquely identify an antibody. Currently, there are 16
commercially available Panx1 antibodies listed on the Antibody
Registry. There are many more that were privately generated and
used in publications such Bargiotas et al. (2011); Huang et al.
(2007). Again, we include the identifiers for our four antibodies
in the materials and methods of the paper, so that text mining
algorithms and authors can identify the usage of these antibod-
ies without ambiguity. If such identifiers were routinely used,
researchers could pull out all papers that use a particular reagent.
More importantly, if problems like specificity come to light, noti-
fications can be placed on those papers whose results may need to
be re-analyzed or re-interpreted.
A second best practice is to publish all the data from a paper
rather than selecting only the best exemplars. In our case, we show
all Western blots for all antibodies and provide access to the full
resolution brain maps via the CCDB. We believe that for novel
proteins or those for which it is difficult to develop good probes,
the type of survey study we publish here provides a public platform
and forum, for evaluating the specificity of the reagents and ensur-
ing that problems with these reagents are widely disseminated
rather than suppressed. Often times, such knowledge is known by
experts in the field, but it may take years for this knowledge to
4http://neuinfo.org
5http://antibodyregistry.org
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percolate to the wider community (MacArthur, 2012), leading to
continued use of faulty reagents during this time.
Finally, ensuring that papers are published in open access jour-
nals or deposited within Pub Med Central or made available
through a pre-print service is critical, to ensure that search engines
can gain access to the Materials and Methods section of the paper.
Thus, with this study we attempt to promote explorations that
move beyond the question of why peptide specific antibodies do
and do not label in brain tissue and instead examine how they
work differently, the complexity of the biological system and how
to interpret further imaging experiments. Our imaging strategy
provides a novel approach such that we release the datasets (mon-
tages, associated metadata, and “raw” images) in the CCDB in
their full size, resolution and complexity rather than presenting
only down-sampled and/or redacted images that one typically
finds in publications. By doing so, this unrestricted available data
rich resource promotes further data mining and explorations by
the public. Other resources like the Allen Brain Atlas and GEN-
SAT may be useful for interpreting our datasets. The Allen Brain
Atlas, a publicly available image database for in situ hybridiza-
tion images of mouse brain and associated tools for information
extraction and visualization (Lein et al., 2007), is very useful as
a first step for correlating with gene expression hotspots. The
Gene Expression Nervous System Atlas (GENSAT) project uses
bacterial artificial chromosome (BAC) vectors in combination
with transgenic mouse to EGFP tag proteins in the CNS for light
microscopy (Gong et al., 2003). While, transgenic Panx1-EGFP is
not yet available in this on-line digital atlas and there is the risk
that recombinant Panx1-EGFP may not traffic the same as wild
type protein, the GENSAT database can be used to correlate with
other proteins in the database for overlap in expression patterns.
The 18 montages from this study significantly increase the num-
ber and expanse of published images of Panx1 labeling in brain.
However, no comprehensive protein expression atlas yet exists for
the rodent brain, equivalent in breadth to the Allen Brain Atlas.
As we see here, antibody labeling is highly variable and dependent
on specimen preparation protocols, even with antibodies to the
same protein. Our study points out the importance of thorough
characterization and unambiguous identification of the antibody
reagents used to report findings. Currently, identification of anti-
body reagents from published studies is very difficult, as most
authors do not provide enough detailed information (e.g., catalog
number) to identify the exact antibody used (Bandrowski et al.,
submitted). The Neurosciences Informatics Framework (NIF6)
has created a large antibody registry where antibodies receive a
uniform resource identifier (URI) that can be used to reference
these reagents in papers (see Table 17). We encourage the use of
these numbers in their papers.
In summary, because this situation occurs more frequently than
is documented, we recommend the following protocol: (1) Entire
data sets should be made available on-line, (2) Reagents need to be
specified, (3) In order to clarify who else uses these reagents, each
antibody should have a unique URI, like those utilized by NIF.
Reproducibility of reagents and protocols are critical. A recent
editorial in Nature highlighted significant reproducibility issues
in clinical drug trials because of insufficient or selective report-
ing (Begley and Ellis, 2012). Here we embrace the difficulties by
publishing in a form that is fully vetted, showing all the data. By
being able to manipulate the levels via the WIB, researchers can
form their own opinion of the data. We encourage readers to leave
comments via the Frontiers website.
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